DataVXAdvanced SciencePaper
journal article·2023-01Open access

Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)

Qin Liu, Yanhong Chu, Jie Shao, Hanqing Qian, Ju Yang, Huizi Sha, Lanqi Cen, Manman Tian, Qiuping Xu, Fangjun Chen, Yang Yang, Weifeng Wang, Kai Wang, Lixia Yu, Jia Wei, Baorui Liu

Advanced Science· Volume 10· Issue 1
Publisher pageOpen full text
Source abstract

Abstract

Nanovaccine In article number 2203298, Baorui Liu, Jia Wei, and co-workers prepare a personalized neoantigen nanovaccine (PNVAC) which spatially displays impressively enhanced lymph nodes trafficking capacity, and functionally induces more mature dendritic cells (DCs), neoantigen-specific T cells, and memory effector T cells. The PNVAC demonstrates superior protective efficacy against advanced gastric cancer recurrence and longer survival in preclinical studies and a phase I clinical trial.
Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Cancer Immunotherapy and Biomarkers · Immune Cell Function and Interaction · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References

Reference metadata was not supplied for this record.